Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690354 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| SCHEMBL13363702 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| SCHEMBL5978273 | 0.93 | SMN1; SMN2 (0.42) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| SCHEMBL7466138 | 0.91 | KDM4E (0.42) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| SCHEMBL6273385 | 0.91 | LMNA (0.45) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| SCHEMBL19440670 | 0.91 | EPHX1 (0.45) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| SCHEMBL28418543 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL5661 | 0.85 | — | — | |
| SCHEMBL9797557 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2EPHX1GAAMAPTKDM4E | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2EPHX1GAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | claimed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| EP-4308638-A1 | USE OF A STABILIZER COMPOSITION FOR STABILIZING POLYOLEFIN RECYCLATES, STABILIZER COMPOSITION, MASTER BATCH CONCENTRATE, PLASTIC COMPOSITION, MOLDING COMPOUND OR MOLDING, METHOD FOR STABILIZING A POLYOLEFIN RECYCLATE AND USE OF A PLASTIC COMPOSITION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-01-24 | — | — | EP | claimed |
| EP-4139387-A1 | ADDITIVE COMPOSITION AND USE THEREOF, CONDENSATION POLYMER COMPOSITION, MOLDING COMPOUND AND MOLDING COMPOUNDS PRODUCED THEREFROM, AND MOLDED PARTS AND USE THEREOF | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-03-01 | — | — | EP | claimed |
| EP-4139385-A1 | USE OF INORGANIC SULPHITES AND/OR THIOSULPHATES FOR STABILISING ALIPHATIC POLYESTERS, STABILISED MOULDING COMPOSITIONS AND MOULDING COMPOSITIONS AND MOULDED PARTS PRODUCED THEREFROM | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-03-01 | — | — | EP | claimed |
| EP-4139384-A1 | ADDITIVE COMPOSITION AND USE THEREOF, CONDENSATION POLYMER COMPOSITION, MOLDING COMPOUND AND MOLDING COMPOUNDS PRODUCED THEREFROM, AND MOLDED PARTS AND USE THEREOF | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-03-01 | — | — | EP | claimed |
| EP-4139388-A1 | USE OF HYDROXYCARBOXYLIC ACID SALTS FOR STABILIZING THERMOPLASTIC CONDENSATION POLYMERS, STABILIZED MOULDING COMPOSITIONS AND MOULDING COMPOSITIONS PRODUCED THEREFROM | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-03-01 | — | — | EP | claimed |
| WO-2022194672-A1 | USE OF A STABILIZER COMPOSITION FOR STABILIZING POLYOLEFIN RECYCLATES, STABILIZER COMPOSITION, MASTER BATCH CONCENTRATE, PLASTIC COMPOSITION, MOLDING COMPOUND OR MOLDING, METHOD FOR STABILIZING A POLYOLEFIN RECYCLATE AND USE OF A PLASTIC COMPOSITION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-09-22 | — | — | WO | claimed |
| EP-3911699-A1 | USE OF AN ADDITIVE COMPOSITION FOR THE CONTROLLED ACCELERATED DECOMPOSITION OF CONDENSATION POLYMERS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2021-11-24 | — | — | EP | claimed |
| EP-0946589-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | claimed |
| EP-0946596-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | claimed |
| EP-0932618-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | AstraZeneca AB (SE) | 1999-08-04 | — | — | EP | claimed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | claimed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | claimed |
| WO-1998025951-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | claimed |
| WO-1998023644-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-06-04 | — | — | WO | claimed |
| WO-1998017680-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ZENECA LIMITED (GB) | 1998-04-30 | — | — | WO | claimed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | claimed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | SMN1; SMN2 2824/4885EPHX1 2769/4885GAA 2040/4885 |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | SMN1; SMN2 2824/4885EPHX1 2769/4885GAA 2040/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3096/4885EPHX1 3217/4885GAA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.